Hikma to Keep Injectable-Drug Unit After Completing Review

Hikma Pharmaceuticals Plc will keep its injectable-drug business after concluding a review of the unit, saying the long-term growth potential is excellent. The stock fell as much as 8.4 percent in London.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.